Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results

详细信息    查看全文

• 作者：Hervé ; Fernandez^a ; ^b ; ^c ; ^{herve.fernandez@aphp.fr} ; Torsten Schmidt^d ; Martin Powell^e ; Ana Patrí ; cia Freitas Costa^f ; Pablo Arriagada^g ; Christian Thaler^h
• 关键词：Bleeding ; Pain ; Quality of life ; Ulipristal acetate ; Uterine fibroids
• 刊名：European Journal of Obstetrics & Gynecology and Reproductive Biology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：208
• 期：Complete
• 页码：91-96
• 全文大小：300 K
• 卷排序：208

文摘

To characterize and describe treatment with Ulipristal acetate (UPA) in a pre-operative setting and to evaluate the safety, effectiveness, and Health Related Quality of Life (HRQoL) outcomes in a population treated according to standard clinical practice in the EU.Study designMulti-centre, prospective, non-interventional study (PREMYA) of patients diagnosed with moderate to severe symptoms of uterine fibroids and undergoing a pre-operative treatment with UPA (Esmya®) at 73 clinical practice sites within the EU. Patients were followed during UPA treatment and for 12 months after treatment discontinuation for a total of 15 months follow-up. Data was collected every 3 months in accordance with standard care visits.ResultsA total of 1568 women were enrolled, of whom 1473 were found to be eligible for data analysis. Only 38.8% of patients underwent surgery, of which the majority were of a conservative/minimally invasive nature. Physicians’ assessments of patients’ overall symptomatic change, as measured on the Clinical Global Impression-Improvement (CGI-I) scale, indicated that 60% of patients were much improved or very much improved at 3 months. Pain and quality of life after treatment cessation remain lower than baseline during the entire period of follow-upConclusionsThe majority of patients do not undergo surgery immediately after treatment cessation. Quality of life and pain are highly improved by Esmya® treatment.